EMAIL THIS PAGE TO A FRIEND

Langmuir : the ACS journal of surfaces and colloids

Controlling anisotropic drug diffusion in lipid-Fe3O4 nanoparticle hybrid mesophases by magnetic alignment.


PMID 23302008

Abstract

We present a new strategy to control the anisotropic diffusion of hydrophilic drugs in lyotropic liquid crystals via the dispersion of magnetic nanoparticles in the mesophase, followed by reorientation of the mesophase domains via an external magnetic field. We select a lipid reverse hexagonal phase doped with magnetic iron oxide nanoparticles and glucose and caffeine as model hybrid mesophase and hydrophilic drugs, respectively. Upon cooling through the disorder-order phase transition of the hexagonal phase and under exposure to an external moderate magnetic field (1.1 T), both the nanoparticles and the hexagonal domains align with their columnar axes along the field direction. As a result, the water nanochannels of the inverted hexagonal domains also align parallel to the field direction, leading to a drug diffusion coefficient parallel to the field direction much larger than what was measured perpendicularly: in the case of glucose, for example, this difference in diffusion coefficients approaches 1 order of magnitude. Drug diffusion of the unaligned reverse hexagonal phase, which consists of randomly distributed domains, shows values in between the parallel and transversal diffusion values. This study shows that modifying the overall alignment of anisotropic mesophases via moderate external fields is a valuable means to control the corresponding transport tensor of the mesophase and demonstrates that the orientation of the domains plays an important role in the diffusion process of foreign hydrophilic molecules.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

183164
(R)-(+)-Limonene, 97%
C10H16
62118
(R)-(+)-Limonene, analytical standard
C10H16
62122
(R)-(+)-Limonene, technical, ~90% (sum of enantiomers, GC)
C10H16
62120
(R)-(+)-Limonene, purum, ≥96.0% (sum of enantiomers, GC)
C10H16
62128
(S)-(−)-Limonene, analytical standard
C10H16
W504505
(S)-(−)-Limonene, ≥95%, FG
C10H16
218367
(S)-(−)-Limonene, 96%
C10H16
M7640
1-Linoleoyl-rac-glycerol, ≥97%, liquid
C21H38O4
334111
Dipentene, technical, for use as solvent (for the paint industry), mixture of various terpenes
C10H16
W524905
Dipentene, mixture of isomers
C10H16
G0400006 Glycerol monolinoleate, European Pharmacopoeia (EP) Reference Standard
C21H38O4
725358
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
725331
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
700312
Iron oxide(II,III), magnetic nanoparticles solution, 10 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
700304
Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
725366
Iron oxide(II,III), magnetic nanoparticles solution, 20 nm avg. part. size, 5 mg/mL in H2O
Fe3O4
700320
Iron oxide(II,III), magnetic nanoparticles solution, 5 nm avg. part. size, 5 mg/mL in toluene
Fe3O4
637106
Iron(II,III) oxide, nanopowder, 50-100 nm particle size (SEM), 97% trace metals basis
Fe3O4
310069
Iron(II,III) oxide, powder, <5 μm, 95%
Fe3O4
518158
Iron(II,III) oxide, 99.99% trace metals basis
Fe3O4